<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118530</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00041321</org_study_id>
    <nct_id>NCT04118530</nct_id>
  </id_info>
  <brief_title>Long Term Arrhythmia Risk and Cardiovascular Events in Hemtopoietic Stem Cell Transplant Survivors: Reveal Linq Cancer Registry Study</brief_title>
  <acronym>ARCHER</acronym>
  <official_title>Long Term Arrhythmia Risk and Cardiovascular Events in Hemtopoietic Stem Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand the following aims:

        1. Aim 1: To evaluate the rate of recurrent AF/AFL in HCST patients with incident AF/AFL
           identified during the initial 30 days of the transplant

        2. Aim 2: To evaluate incident episodes of 1) stroke/TIA; 2) other thromboembolic events
           (not stroke/TIA); 3) Heart failure events; 4) Ischemic heart events

        3. Aim 3: To evaluate overall implantation safety in this population
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Recurrent AF/AFL episodes</measure>
    <time_frame>1 year</time_frame>
    <description>Any recurrent episodes of AF/AFL lasting ≥2 minutes identified in ICM monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incident Episodes of Interest</measure>
    <time_frame>1 year</time_frame>
    <description>Incident episodes of: stroke/TIA; other thromboembolic events (not stroke/TIA); Heart failure events; ischemic heart events. Overall device implantation safety.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hematopoietic Stem Cell Transplant</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplant (HSCT) Patients</arm_group_label>
    <description>- Patients with incidence of AF/AFL in the first 30 days of transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HSCT Patients</intervention_name>
    <description>Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant (HSCT) Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with the diagnosis that requires them to undergo HSCT who develop incident
        AF/AFL in the first 30 days of transplant.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18

          2. CHADS-VASc ≥ 2

          3. Recovery of platelets to &gt;50,000 within 90 days of incident atrial fibrillation (AF)
             diagnosis

          4. Discharge from the incident stem cell transplant (SCT) hospitalization

          5. Normal sinus rhythm at the time of consent

        Exclusion Criteria:

          1. Prior history of atrial fibrillation (AF) or atrial flutter

          2. CHADS-VASc &lt;2

          3. Platelets &lt;50,000 after 90 days post transplantation

          4. Continued SCT hospitalization at 90 days

          5. Inability to receive anticoagulation

          6. AF or other arrhythmia at the time of consent

          7. Current use of a class IC or III antiarrhythmic medication

          8. Inability to provide informed consent/significant cognitive impairment

          9. Expected survival less than one year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Fradley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida, Department of Internal Medicine, Division of Cardiovascular Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Glunk, BSN, RN, ACRP-CP</last_name>
    <phone>813-259-0671</phone>
    <email>hglunk@health.usf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nhi Tran, MS</last_name>
    <phone>813-259-0628</phone>
    <email>nntran@health.usf.edu</email>
  </overall_contact_backup>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 5, 2019</study_first_submitted>
  <study_first_submitted_qc>October 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>October 5, 2019</last_update_submitted>
  <last_update_submitted_qc>October 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Florida</investigator_affiliation>
    <investigator_full_name>Michael Fradley</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Hematopoietic Stem Cell Transplant</keyword>
  <keyword>Atrial Flutter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

